the detrimental consequences of associated atherothrombotic disease. A large body of literature strongly suggests that cigarette smoke unfavourably influences all major stages of atherosclerosis ...

This Review provides a state-of-the-art account of the available evidence on antithrombotic therapies for the secondary prevention of atherothrombotic events in patients with concomitant CAD and ...

Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. We randomly assigned 15,603 ...

6,7 This study, called the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P)–Thrombolysis in Myocardial Infarction (TIMI) 50 trial, was designed ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of extended therapy with ticagrelor 60 mg twice daily plus aspirin (hereafter referred to as ticagrelor), ...

We appreciate the suggestion by Craig McLachlan and associates of the possibility of rebound atherothrombotic events after cessation of clopidogrel administration in susceptible people, such as those ...

We then investigated the influence of this genotype on risk of atherothrombotic events among patients taking clopidogrel after coronary angioplasty with stent implantation (phase 2). The study ...

Ticagrelor 60 mg twice daily, co‑administered with aspirin (acetylsalicylic acid), has a marketing authorisation for 'the prevention of atherothrombotic events in adult patients with a history of ...

When researchers looked specifically at people who had another stroke after an atherothrombotic stroke, they found that 14 out of 114 people with normal triglyceride levels, or 12%, had one during ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Myocardial infarction (MI) causes millions of deaths worldwide. Though there have been advances in the survival rates following ST-elevation MI (STEMI), survivors often develop heart failure due ...

Diagnosed prevalent cases of atherothrombotic disease are set to increase steadily, driving the market to increase from $36 billion in 2012 to $47 billion in 2022, according to new forecasts.